https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-25 16:32:332016-11-25 16:35:492013 ASH: First Clinical Results of a randomized Phase 2 study of SGI-110 in adult patients with AML
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-25 16:29:522016-11-25 16:30:142013 ASH: Determinants of Demethylation and Clinical Response in AML patients treated with SGI-110
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-20 16:30:202016-11-25 16:30:462013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-15 16:30:522016-11-25 16:31:142013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-10 16:31:242016-11-25 16:31:502013 ECCO: Study of correlation baseline biomarkers and DNA demethylation to clin response of SGI-11
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-07 16:32:542016-11-25 16:33:262013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-06 16:33:312016-11-25 16:33:522013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2013-11-04 16:34:012016-11-25 16:34:262013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
